First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

Brazil authorizes Butanvac vaccine for volunteers in cl...



Brazil authorizes Butanvac vaccine for volunteers in clinical trial

Healthcare workers treat patients inside a Covid-19 intensive care unit (ICU) at a field hospital in the Heliopolis favela of Sao Paulo, Brazil, on Friday, March 19, 2021. States across the country are seeing ICU bed shortages and healthcare systems on the brink of collapse, including Sao Paulo which has hit 91% capacity. Photographer: Jonne Roriz/Bloomberg via Getty Images
By Reuters
08 Jul 2021 0

BRASILIA, July 7 (Reuters) - Brazilian health regulator Anvisa on Wednesday gave the go-ahead for the Butanvac COVID-19 vaccine developed by Sao Paulo's Butantan Institute biomedical center to be used on volunteers in clinical trials.

Anvisa in a statement said the vaccine will be applied in two doses, 28 days apart. Phase I of Butanvac’s clinical trial will involve 400 volunteers, and the first two phases are expected to involve 6,000 volunteers in total.

In a separate statement, Butantan said the tests will begin in the coming days in Riberao Preto, a city in the state of Sao Paulo.

Butantan said it has around 10 million doses of the Butanvac shot in stock, which will be used to assess the vaccine’s safety and efficacy in the trials. It hopes to have 40 million shots ready for use by October, it added.

Brazil registered 54,022 new COVID-19 cases and 1,648 new deaths in the past 24 hours, the Health Ministry said on Wednesday. This brings the total in Brazil to nearly 18.9 million cases and 528,540 deaths.

(Reporting by Jamie McGeever and Eduardo Simoes; Editing by Leslie Adler and Bill Berkrot)

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]


Please peer review 3 community comments before your comment can be posted